DC Field | Value | Language |
---|---|---|
dc.contributor.author | Haiyoung Jung | - |
dc.contributor.author | Suk Ran Yoon | - |
dc.contributor.author | Jeewon Lim | - |
dc.contributor.author | Hee Jun Cho | - |
dc.contributor.author | Hee Gu Lee | - |
dc.date.accessioned | 2020-09-24T03:13:29Z | - |
dc.date.available | 2020-09-24T03:13:29Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/22652 | - |
dc.description.abstract | Rho GTPases play central roles in numerous cellular processes, including cell motility, cell polarity, and cell cycle progression, by regulating actin cytoskeletal dynamics and cell adhesion. Dysregulation of Rho GTPase signaling is observed in a broad range of human cancers, and is associated with cancer development and malignant phenotypes, including metastasis and chemoresistance. Rho GTPase activity is precisely controlled by guanine nucleotide exchange factors, GTPase-activating proteins, and guanine nucleotide dissociation inhibitors. Recent evidence demonstrates that it is also regulated by post-translational modifications, such as phosphorylation, ubiquitination, and sumoylation. Here, we review the current knowledge on the role of Rho GTPases, and the precise mechanisms controlling their activity in the regulation of cancer progression. In addition, we discuss targeting strategies for the development of new drugs to improve cancer therapy. | - |
dc.publisher | MDPI | - |
dc.title | Dysregulation of Rho GTPases in human cancers | - |
dc.title.alternative | Dysregulation of Rho GTPases in human cancers | - |
dc.type | Article | - |
dc.citation.title | Cancers | - |
dc.citation.number | 5 | - |
dc.citation.endPage | 1179 | - |
dc.citation.startPage | 1179 | - |
dc.citation.volume | 12 | - |
dc.contributor.affiliatedAuthor | Haiyoung Jung | - |
dc.contributor.affiliatedAuthor | Suk Ran Yoon | - |
dc.contributor.affiliatedAuthor | Jeewon Lim | - |
dc.contributor.affiliatedAuthor | Hee Jun Cho | - |
dc.contributor.affiliatedAuthor | Hee Gu Lee | - |
dc.contributor.alternativeName | 정해용 | - |
dc.contributor.alternativeName | 윤석란 | - |
dc.contributor.alternativeName | 임지원 | - |
dc.contributor.alternativeName | 조희준 | - |
dc.contributor.alternativeName | 이희구 | - |
dc.identifier.bibliographicCitation | Cancers, vol. 12, no. 5, pp. 1179-1179 | - |
dc.identifier.doi | 10.3390/cancers12051179 | - |
dc.subject.keyword | Cancer | - |
dc.subject.keyword | Chemoresistance | - |
dc.subject.keyword | Metastasis | - |
dc.subject.keyword | Migration | - |
dc.subject.keyword | Rho GTPases | - |
dc.subject.local | Cancers | - |
dc.subject.local | cancer | - |
dc.subject.local | Cancer | - |
dc.subject.local | chemoresistance | - |
dc.subject.local | Chemoresistance | - |
dc.subject.local | Chemo-resistance | - |
dc.subject.local | metastasis | - |
dc.subject.local | Metastasis | - |
dc.subject.local | Migration | - |
dc.subject.local | migration | - |
dc.subject.local | Rho GTPases | - |
dc.description.journalClass | Y | - |
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.